p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
about
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsNutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian CarcinomasClinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Dystrophin is a tumor suppressor in human cancers with myogenic programs.Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy.Targeting Disease Persistence in Gastrointestinal Stromal TumorsFAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors.Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cellsGenomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumorsMAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imagingCell cycle and dystrophin dysregulation in GIST.ETV1-Positive Cells Give Rise to BRAFV600E -Mutant Gastrointestinal Stromal Tumors.Emerging drugs for the treatment of gastrointestinal stromal tumour.New targets and therapies for gastrointestinal stromal tumors.The expression of MDM2 in gastrointestinal stromal tumors: immunohistochemical analysis of 35 cases.p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib.Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib.
P2860
Q26799387-302DEB4F-969A-4ADA-A1FC-93908596EC3BQ28547093-F47718D8-A017-4371-ADCC-4FAB57E7EBBBQ33633431-A483AAE7-9BAE-4EF0-9044-3CA35FAB286DQ34479070-520246E9-59CA-4435-AD8E-05F5D82AAE44Q34973753-85123A02-1F6D-4E5F-8204-849792785456Q35497448-AFFC4CE7-843E-4B2A-9F35-BF3C3887487FQ35777530-33441003-7C12-46E8-83F5-79E24FABC70DQ35836497-530A08F6-667F-441C-A0BD-81E64E33FF3EQ36798652-790613B3-4DCC-4464-8694-1A226DD28018Q37663907-51B57C5F-7E85-4097-89F4-E2647BAC71D9Q37692151-CA0DDEFD-6753-4BB5-81A2-2A8907EA6042Q39042562-4C0504FB-A39F-4BF5-8E16-5B6EC6CAEEFCQ41694334-ED881BED-2E3D-4AD2-B09E-3A0EBBF98ADBQ41963175-AE88F4DF-F298-4473-A3B6-1DBC4DBF9D6CQ43209031-B8B45D68-ABE3-4A00-B604-D97D0BD638DCQ46050114-E0E00839-7BD1-4BC6-8EAA-6AB7F0268891Q47355982-92033A6D-66AA-4F1F-B160-6CCF34797363Q47432725-83234455-93DF-4239-80C1-C911CE6C1FD8Q48095326-1D0A64CE-9460-4398-AF6F-6A2079AB39FAQ48166615-AFE7C835-7720-4DD5-B135-105635DB2A50Q49924821-3DA9FC77-8D3B-43C0-9B46-4464C4713236Q51232554-146F4D5C-DFD5-4B5E-AEA1-1995921DAD0CQ53576519-AC689D4C-EC8F-4FF4-9FBB-15B1933B676F
P2860
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@ast
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@en
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@nl
type
label
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@ast
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@en
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@nl
prefLabel
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@ast
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@en
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@nl
P2093
P2860
P1433
P1476
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors
@en
P2093
Brian Rubin
Florian Grabellus
Georg Taeger
Joern Henze
Jonathan A Fletcher
Juergen Treckmann
Martin Schuler
Sebastian Bauer
Susanne Simon
Takahiro Taguchi
P2860
P304
P356
10.1371/JOURNAL.PONE.0037776
P407
P577
2012-01-01T00:00:00Z